I'm not saying it's not working, I'm saying we should look into the reasons that a new and apparently "revolutionary" therapy is only growing at 5% as per same quarter last year.
And of course, in Australia, we don't worry about cost of therapies (mostly) as the cost for public patients is covered by public healthcare.
I was referring to America, where this isn't the case, and where the company is attempting to get approval.
MSB $1 Party, page-403
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.63 |
Change
0.050(3.17%) |
Mkt cap ! $1.798B | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.65 | $1.62 | $1.073M | 657.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 10738 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.63 | 47259 | 5 |
View Market Depth
| Last trade - 10.22am 19/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |